US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

ImageneBio, Inc. - Common Stock (NQ:IMA)

4.100 +0.050 (+1.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImageneBio, Inc. - Common Stock

News headline image
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Reports Second Quarter 2026 Financial Results
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Appoints Matt Robbins as General Counsel
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies 
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
Via AB Newswire
News headline image
ImageneBio Announces $30 Million Private Placement
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio to Participate in Leerink Global Healthcare Conference
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
From ImageneBio, Inc.
Via GlobeNewswire